secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-07-02T23:59:59+00:00
Accession:  0001140361-24-032080
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian raises $130M via PIPE; Phase 2b MG trial meets primary endpoint, 71% responder rate
--------------------------------------------------------------------------------

- Raised ~$130M by selling 3.56M common shares and 2.94M Series B convertible preferred shares at $20 each.
- Phase 2b trial of Descartes-08 in myasthenia gravis met primary endpoint: 71% of treated patients had ≥5-point MGC improvement vs 25% placebo (p=0.018).
- Descartes-08 well tolerated with no cytokine release syndrome or neurotoxicity; supports outpatient administration without preconditioning chemo.
- Appointed Kemal Malik, MBBS to Board; first patient dosed in Phase 2 SLE trial of Descartes-08.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/0001140361-24-032080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000114036124032080/ef20031962_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-032080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer